Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31825569

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2020 Feb 13
First author
Murthy RK

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2020 Feb 6;382(6):586. doi: 10.1056/NEJMx190039.
    note
    Source null
    related pmid
    31881136
    relationship
    Erratum in
  2. citation
    Nat Rev Clin Oncol. 2020 Mar;17(3):133. doi: 10.1038/s41571-019-0325-y.
    note
    Source null
    related pmid
    31900443
    relationship
    Comment in
  3. citation
    N Engl J Med. 2020 Feb 13;382(7):669-671. doi: 10.1056/NEJMe1916310.
    note
    Source null
    related pmid
    32053305
    relationship
    Comment in
  4. citation
    Cancer. 2020 May 15;126(10):2113. doi: 10.1002/cncr.32918.
    note
    Source null
    related pmid
    32343407
    relationship
    Comment in
  5. citation
    N Engl J Med. 2020 Jun 18;382(25):e98. doi: 10.1056/NEJMc2004854.
    note
    Source null
    related pmid
    32558479
    relationship
    Comment in

Authors and identifiers

  1. name
    Murthy RK
    type
    Author
  2. name
    Loi S
    type
    Author
  3. name
    Okines A
    type
    Author
  4. name
    Paplomata E
    type
    Author
  5. name
    Hamilton E
    type
    Author
  6. name
    Hurvitz SA
    type
    Author
  7. name
    Lin NU
    type
    Author
  8. name
    Borges V
    type
    Author
  9. name
    Abramson V
    type
    Author
  10. name
    Anders C
    type
    Author
  11. name
    Bedard PL
    type
    Author
  12. name
    Oliveira M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Murthy RK
    type
    Author
  2. name
    Loi S
    type
    Author
  3. name
    Okines A
    type
    Author
  4. name
    Paplomata E
    type
    Author
  5. name
    Hamilton E
    type
    Author
  6. name
    Hurvitz SA
    type
    Author
  7. name
    Lin NU
    type
    Author
  8. name
    Borges V
    type
    Author
  9. name
    Abramson V
    type
    Author
  10. name
    Anders C
    type
    Author
  11. name
    Bedard PL
    type
    Author
  12. name
    Oliveira M
    type
    Author
bibliography ids
  1. nci-bib-dadbe4b1dbd3d9b39713013b
book metadata
content sha256
a70e11fb203984bdb85a38b6b782ca4cc9f977ed1597b0fafbbae8167e4872f1
document type
citation
dois
  1. 10.1056/NEJMoa1914609
electronic publication date
display
2019 Dec 11
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31825569
immutable id
pubmed:31825569@a70e11fb203984bdb85a38b6b782ca4cc9f977ed1597b0fafbbae8167e4872f1
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
7
name
The New England journal of medicine
nlm unique id
0255562
pages
597-609
volume
382
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2020 Feb 6;382(6):586. doi: 10.1056/NEJMx190039.
    note
    Source null
    related pmid
    31881136
    relationship
    Erratum in
  2. citation
    Nat Rev Clin Oncol. 2020 Mar;17(3):133. doi: 10.1038/s41571-019-0325-y.
    note
    Source null
    related pmid
    31900443
    relationship
    Comment in
  3. citation
    N Engl J Med. 2020 Feb 13;382(7):669-671. doi: 10.1056/NEJMe1916310.
    note
    Source null
    related pmid
    32053305
    relationship
    Comment in
  4. citation
    Cancer. 2020 May 15;126(10):2113. doi: 10.1002/cncr.32918.
    note
    Source null
    related pmid
    32343407
    relationship
    Comment in
  5. citation
    N Engl J Med. 2020 Jun 18;382(25):e98. doi: 10.1056/NEJMc2004854.
    note
    Source null
    related pmid
    32558479
    relationship
    Comment in
outcomes validated
false
pmid
31825569
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
2987a98bcfbd6fc732e4df52aabd0b24b8f723e8b6207b0b57b2ec024f49a347
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Feb 13
precision
day
year
2020
publication types
  1. Journal Article
  2. Multicenter Study
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31825569/
title
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Preserved source evidence · Not medical advice